In the STEP 1 trial, participants taking Wegovy alongside diet and exercise lost an average of nearly 15% of their body weight over 68 weeks
Furthermore, in another meta-analysis [23], which excluded ELIXA [24] due to fact that lixisenatide is a short-acting GLP-1RA and all participants had acute coronary syndrome, GLP-1RAs were associated with significant reductions in MACE (HR 0.85, 95% CI 0.800.90), cardiovascular death (HR 0.85, 95% CI 0.780.93), stroke (HR 0.81, 95% CI 0.740.90), and myocardial infarction (HR 0.88, 95% CI 0.810.96) (Table 2)
Brainy Babe Cognitive support for focus, clarity, and mental sharpness
These findings help clarify how tirzepatide affects complex metabolic pathways in research settings
Side effects and how to manage them Every tirzepatide formulation, whether brand-name or compounded, comes with a predictable set of side effects